Manuscripts Published in Refereed Journals or in Press



Pseudomonas aeruginosa infection of a Tg(mpx:GFP)uwm1 zebrafish embryo. The myeloperoxidase promoter drives green fluorescent protein (GFP) expression in this transgenic zebrafish strain. GFP-expressing phagocytes are seen within the ventral tail of a zebrafish embryo infected with ~1000 CFU of mCherry-expressing P. aeruginosa strain PAK (red).

(Photos by J. Muse Davis and Mark Brannon)

Thaipisuttikul I, Hittle LE, Chandra R, Zangari D, Dixon CL, Garrett TA, Rasko DA, Dasgupta N, Moskowitz SM, Malmström L, Goodlett DR, Miller SI, Bishop RE, Ernst RK (2014). A divergent Pseudomonas aeruginosa palmitoyl-transferase essential for cystic fibrosis-specific lipid A. Mol Microbiol 91: 158-174. PubMed link

Gutu AD, Sgambati N, Strasbourger P, Brannon MK, Jacobs MA, Haugen E, Kaul RK, Johansen HK, Høiby N, Moskowitz SM (2013). Polymyxin resistance of Pseudomonas phoQ mutants is dependent on additional two-component regulatory systems. Antimicrob Agents Chemother, 57: 2204-2215. PubMed link

Nichols DP, Caceres SM, Caverly L, Fratelli C, Kim SH, Malcolm KC, Poch KR, Saavedra MT, Solomon G, Taylor-Cousar JL, Moskowitz SM, Nick JA (2013). Effects of azithromycin in Pseudomonas aeruginosa burn wound infection. J Surg Res, 183: 767-776. PubMed link

Rada B, Jendrysik MA, Pang L, Hayes CP, Yoo DG, Park JJ, Moskowitz SM, Malech HL, Leto TL (2013). Pyocyanin-enhanced neutrophil extracellular trap formation requires the NADPH oxidase. PLoS ONE 8: e54205. PubMed link

Moskowitz SM, Brannon MK, Dasgupta N, Pier M, Sgambati N, Miller AK, Selgrade SE, Miller SI, Denton M, Conway SP, Johansen HK, Hoiby N (2012). PmrB mutations promote polymyxin resistance of Pseudomonas aeruginosa isolated from colistin-treated cystic fibrosis patients. Antimicrob Agents Chemother 56: 1019-1030. PubMed link

Miller AK, Brannon MK, Stevens L, Johansen HK, Selgrade SE, Miller SI, Høiby N, Moskowitz SM (2011). PhoQ mutations promote lipid A modification and polymyxin resistance of Pseudomonas aeruginosa found in colistin-treated cystic fibrosis patients. Antimicrob Agents Chemother 55: 5761-5769. PubMed link

Young RL, Malcolm KC, Kret JE, Caceres SM, Poch KR, Nichols DP, Taylor-Cousar JL, Saavedra MT, Randell SH, Vasil ML, Burns JL, Moskowitz SM, Nick JA (2011). Neutrophil Extracellular Trap (NET)-mediated killing of Pseudomonas aeruginosa: Evidence of acquired resistance within the CF airway, independent of CFTR. PLoS ONE 6: e23637. PubMed link

Moskowitz SM, Emerson JC, McNamara S, Shell RD, Orenstein DM, Rosenbluth D, Katz MF, Ahrens R, Hornick D, Joseph P, Gibson RL, Aitken ML, Benton WW, Burns JL (2010).Randomized trial of biofilm testing to select antibiotics for cystic fibrosis airway infection. Pediatr Pulmonol 46: 184-192. PubMed link

Moskowitz SM, Garber E, Chen Y, Clock SA, Tabibi S, Miller AK, Doctor M, Saiman L (2010).Colistin susceptibility testing: Evaluation of reliability for cystic fibrosis isolates of Pseudomonas aeruginosa and Stenotrophomonas maltophilia. J Antimicrob Chemother 65: 1416-1423. PubMed link

Moskowitz SM, Ernst RK (2010). The role of Pseudomonas lipopolysaccharide in cystic fibrosis airway infection. Subcell Biochem 53: 241-253. PubMed link

Moskowitz SM, Wiener-Kronish JP (2010). Mechanisms of bacterial virulence in pulmonary infections. Curr Opin Crit Care 16: 8-12. PubMed link

Brannon MK, Davis JM, Mathias JR, Hall CJ, Emerson JC, Crosier PS, Huttenlocher A, Ramakrishnan L, Moskowitz SM (2009). Pseudomonas aeruginosa Type III secretion system interacts with phagocytes to modulate systemic infection of zebrafish embryos. Cell Microbiol 11: 755-768. PubMed link

Moskowitz SM, Chmiel JF, Sternen DL, Cheng E, Gibson RL, Marshall SG, Cutting GR (2008). Clinical practice and genetic counseling for cystic fibrosis and CFTR-related disorders. Genet Med 10: 851-868.
PubMed link

Mena A, Smith EE, Burns JL, Speert DP, Moskowitz SM, Perez JL, Oliver A. (2008) Genetic adaptation of Pseudomonas aeruginosa to the airways of cystic fibrosis patients is catalyzed by hypermutation. J Bacteriol 190: 7910-7917. PubMed link

Moskowitz SM, Silva SJ, Mayer-Hamblett N, Pasta DJ, Mink DR, Mabie JA, Konstan MW, Wagener JS (2008). Shifting patterns of inhaled antibiotic use in cystic fibrosis. Pediatr Pulmonol 43: 874-881. PubMed link

Johansen HK, Moskowitz SM, Ciofu O, Pressler T, Høiby N (2008). Spread of colistin resistant non-mucoid Pseudomonas aeruginosa among chronically infected Danish cystic fibrosis patients. J Cyst Fibros 7: 391-397. PubMed link

Ernst RK, Moskowitz SM, Emerson JC, Kraig GM, Adams KN, Harvey MD, Ramsey B, Speert DP, Burns JL, Miller SI (2007). Unique lipid A modifications in Pseudomonas aeruginosa isolated from the airways of patients with cystic fibrosis. J Infect Dis 196: 1088-1092. PubMed link

Smith EE, Buckley D, Wu Z, Saenphimmachak C, Hoffman LR, D’Argenio DA, Miller SI, Ramsey BW, Speert D, Moskowitz SM, Burns JL, Kaul R, Olson MV (2006) Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. PNAS 103: 8487-8492. PubMed link

Ernst RK, Adams KN, Moskowitz SM, Kraig GM, Kawasaki K, Stead CM, Trent MS, Miller SI (2006) The Pseudomonas aeruginosa lipid A deacylase: selection for expression and loss within the cystic fibrosis airway. J Bacteriol 188: 191-201. PubMed link

Moskowitz SM, Foster JM, Emerson JC, Gibson RL, Burns JL (2005) Use of Pseudomonas biofilm susceptibilities to assign simulated antibiotic regimens for cystic fibrosis airway infection. J Antimicrob Chemother 56: 879-886. PubMed link

Moskowitz SM, Gibson RL, Effman EL (2005) Cystic fibrosis lung disease: genetic influences, microbial interactions, and radiological assessment. Pediatr Radiol 35: 739-757. PubMed link

Johnson LN, Han J-Y, Moskowitz SM, Burns JL, Qin X, Englund JA (2004) Pandoraea bacteremia in a cystic fibrosis patient with associated systemic illness. Pediatr Infect Dis J 23: 881-882. PubMed link

Moskowitz SM, Foster JM, Emerson J, Burns JL (2004) Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol 42: 1915-1922. PubMed link

Moskowitz SM, Ernst RK, Miller SI (2004) PmrAB, a two-component regulatory system of Pseudomonas aeruginosa that modulates resistance to cationic antimicrobial peptides and addition of aminoarabinose to lipid A. J Bacteriol 186: 575-579. PubMed link

Ernst RK, Hajjar AM, Tsai JH, Moskowitz SM, Wilson CB, Miller SI (2003) Pseudomonas aeruginosa lipid A diversity and its recognition by Toll-like receptor 4. J Endotoxin Res 9: 395-400. PubMed link

Moskowitz SM, Tieu PT, Neufeld EF (1993) Mutation in Scheie syndrome (MPS IS): a G—>A transition creates new splice site in intron 5 of one IDUA allele. Hum Mutat 2: 141-144. PubMed link

Bach G, Moskowitz SM, Tieu PT, Matynia A, Neufeld EF (1993) Molecular analysis of Hurler syndrome in Druze and Muslim Arab patients in Israel: multiple allelic mutations of the IDUA gene in a small geographic area. Am J Hum Genet: 53: 330-338. PubMed link

Moskowitz SM, Tieu PT, Neufeld EF (1993) A deletion/insertion mutation in the IDUA gene in a Libyan Jewish patient with Hurler syndrome (mucopolysaccharidosis IH). Hum Mutat 2: 71-73. PubMed link

Stoltzfus LJ, Sosa-Pineda B, Moskowitz SM, Menon KP, Dlott B, Hooper L, Teplow DB, Shull RM, Neufeld EF (1992) Cloning and characterization of cDNA encoding canine a-L-iduronidase; mRNA deficiency in mucopolysaccharidosis I dog. J Biol Chem 267: 6570-6575. PubMed link

Paw BH, Moskowitz SM, Uhrhammer N, Wright N, Kaback MM, Neufeld EF (1990) Juvenile GM2 gangliosidosis caused by substitution of histidine for arginine at position 499 or 504 of the a-subunit of b-hexosaminidase. J Biol Chem 265: 9452-9457. PubMed link

Other Publications

Moskowitz SM, Chmiel JF, Sternen DL, Cheng E, Cutting GR (updated February 2008). CFTR-Related Disorders in: GeneReviews at GeneTests: Medical Genetics Information Resource (database online). © University of Washington, Seattle. 1997-2008. Available at http://www.genetests.org. Accessed 2/20/08. GeneReviews link

Moskowitz SM (2005) A role for the vanishing physician-scientist? Letter to the editor of J Clin Invest, published on-line Jan. 20th, 2005 [comment on editorial by Marks AR (2005) How to support the basic sciences. J Clin Invest 115:2]. Link to the Journal of Clinical Investigation

Abstracts and Other Presentations

Hoffman LR, Moskowitz SM, Foster JM, Emerson J, Burns JL, Gibson RL (2010) Tobramycin susceptibility of Pseudomonas aeruginosa cystic fibrosis isolates using standard & biofilm methods: relationship with eradication & inflammation. Abstract #330 and poster presentation at the 24th Annual North American CF Conference, Baltimore, Oct. 21st, 2010.

Kim SH, Strasbourger P, Burns JL, Anderson G, Parsek M, Moskowitz SM (2010) In vitro PK-PD analysis of tobramycin and ceftazidime effects on Pseudomonas biofilms. Abstract and poster presentation A1-652, 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, Sept. 13th, 2010.

Moskowitz SM, Silva SJ, Mayer-Hamblett N, Pasta DJ, Mink DR, Wagener JS, Konstan MW, Morgan WJ (2007) Inhaled antibiotic use among North American cystic fibrosis patients. Abstract and poster presentation , American Thoracic Society International Conference, San Francisco, May 23rd, 2007.

Brannon MK, Pier M, Yeung L, Weeks A, Foster J, Burns JL, Krogh Johansen H, Høiby N, Moskowitz SM (2006) Highly colistin-resistant Pseudomonas aeruginosa as an emerging pathogen in cystic fibrosis. Pediatr Pulmonol Supplement 29, abstract and platform presentation at the 20th Annual North American CF Conference, Denver, Nov. 3rd, 2006.

Brannon MK, Pier M, Stevens L, Krogh Johansen H, Høiby N, Moskowitz SM (2006) Polymyxin-resistant Pseudomonas aeruginosa from colistin-treated cystic fibrosis patients: diverse regulatory mutations associated with a specific lipid A phenotype. Abstract and poster presentation C1-958, 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Sept. 28th, 2006.

Brannon MK, Pier M, Stevens L, Yeung L, Ernst RK, Foster J, Morgan W, Burns JL, Oana C, Krogh Johansen H, Høiby N, Moskowitz SM (2005) Colistin-treated cystic fibrosis patients harbor polymyxin-resistant strains of Pseudomonas aeruginosa, some with mutation of PmrAB, a two-component regulator of lipid A structure. Pediatr Pulmonol Supplement 28, abstract 288.

Moskowitz SM, Brannon MK, Ernst RK, Høiby N (2005) Diverse mutational events in polymyxin-resistant Pseudomonas aeruginosa from colistin-treated cystic fibrosis patients are associated with a common pattern of lipid A modification. Poster presented at ASCI/AAP Joint Meeting, Chicago, Apr. 16th, 2005.

Yeung L, Moskowitz SM (2004) Evidence for diverse mutational events in polymyxin-resistant P. aeruginosa from colistin-exposed CF patients. Pediatr Pulmonol Supplement 27: abstract 307.

Moskowitz S, Foster J, Emerson J, Gibson R, McNamara S, Burns J (2003) Discordance of conventional and biofilm antibiotic susceptibilities of Pseudomonas aeruginosa isolated from cystic fibrosis airways. Poster presented at Biofilms 2003, Victoria, British Columbia, Nov. 3rd, 2003; abstract 266.

Krogh-Johansen H, Moskowitz SM, Ciofu O, Ernst RK, Koch C, Høiby N (2003) Spread and clearance of colistin-resistant (CR) Pseudomonas aeruginosa(PA) among chronically infected Danish cystic fibrosis patients. Pediatr Pulmonol Supplement 25: abstract 349.

Moskowitz SM, Foster J, Emerson J, Gibson RL, McNamara S, Burns JL (2003) Development of a numerical algorithm to select antibiotic regimens based on biofilm susceptibilities of CF P. aeruginosa isolates. Pediatr Pulmonol Supplement 25: abstract 335.

Moskowitz SM, Foster J, Emerson JC, Gibson RL, McNamara S, Burns JL (2003) Discordance of conventional and biofilm antibiotic susceptibilities of Pseudomonas aeruginosa isolated from cystic fibrosis airways. AJRCCM 167 (7): abstract 322.

Moskowitz SM, Foster J, Emerson JC, Gibson RL, McNamara S, Burns JL (2003) Discordance of antibiotic regimens based on biofilm and conventional susceptibilities of Pseudomonas aeruginosa from cystic fibrosis patients. Pediatr Res 53 (4): abstract 3230.

Moskowitz SM, Ernst RK, Miller SI (2001) Antimicrobial peptide resistance and regulation of lipid A structure in Pseudomonas aeruginosa.  Poster presented at 3rd Gordon Research Conference on Antimicrobial Peptides, Ventura, CA, March 18th-22nd, 2001.

Moskowitz SM, Burns JL, Nguyen CD, Høiby N, Ernst RK, Miller SI (2000) Polymyxin resistance and lipid A structure of Pseudomonas aeruginosa isolated from colistin-treated and colistin-naîve cystic fibrosis patients. Pediatr Pulmonol Supplement 20: A348.

Moskowitz SM, Ernst RK, Miller SI (2000) Resistance to cationic antimicrobial peptides cause by mutation of pmrA/B, an environmental sensing system that regulates outer membrane structure in Pseudomonas aeruginosa. Pediatr Pulmonol Supplement 20: A297.

Moskowitz SM, Ernst RK, Miller SI (1999) The pmrA/B locus regulates resistance to the cationic antimicrobial peptides polymyxin B and C18G in Pseudomonas aeruginosa.  Pediatr Pulmonol Supplement 19: A339.

Moskowitz SM, Menon KP, Tieu PT, Neufeld EF (1992) Architecture of the gene encoding a-L-iduronidase and some mutations underlying human and canine MPS I.  Am J Hum Genet 51:A53.

Moskowitz SM, Dlott B, Chuang PD, Neufeld EF (1992) Cloning and expression of cDNA encoding the human lysosomal enzyme, a-L-iduronidase.  FASEB J 6:A77.

Site Map